LPCN
Lipocine IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.60M
P/E Ratio
—
EPS
$-1.77
Beta
1.09
52W High
$12.37
52W Low
$1.81
50-Day MA
$8.32
200-Day MA
$4.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
5.64
PEG Ratio
0.00
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.
Fundamentals
| Revenue (TTM) | $1.98M |
| Gross Profit (TTM) | $1.98M |
| EBITDA | $-10.31M |
| Operating Margin | -219.60% |
| Return on Equity | -54.30% |
| Return on Assets | -32.80% |
| Revenue/Share (TTM) | $0.36 |
| Book Value | $2.35 |
| Price-to-Book | 1.03 |
| Price-to-Sales (TTM) | 7.39 |
| EV/Revenue | 0.0172 |
| EV/EBITDA | 153.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -67.20% |
| Shares Outstanding | $7.30M |
| Float | $6.61M |
| % Insiders | 2.16% |
| % Institutions | 23.29% |
Analyst Ratings
Consensus ($11.00 target)
2
BuyData last updated: 4/8/2026